Skip to content

A randomized controlled trial for YiFei moxibustion treatment of COPD based on the regulation of NF?B/TGF-beta 1/Smad2 signaling pathway

A randomized controlled trial for YiFei moxibustion treatment of COPD based on the regulation of NF?B/TGF-beta 1/Smad2 signaling pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026484
Enrollment
Unknown
Registered
2019-10-12
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Sponsors

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis was consistent with Stable Chronic Obstructive Pulmonary Disease; 2. The patient dialectical accord with Lung Qi Deficiency, Lung Spleen Qi Deficiency, Lung and Kidney Qi Deficiency patients; 3. Aged 40 to 75 years; 4. Able to tolerante YiFei moxibustion and voluntarily to join the study.

Exclusion criteria

Exclusion criteria: 1. Patients with serious heart, brain, liver, kidney and other system diseases; 2. Patients with other serious lung disease; 3. Pregnant and lactating patients; 4. Patients with mental illness and consciousness disturbance; 5. Patients with poor compliance; 6. There are patients who are allergic to the drugs involved in YiFei moxibustion; 7. Patients who cannot undergo bronchoscopic alveolar lavage: (1) The coagulation mechanism is severely impaired (2) Cardiac insufficiency, severe arrhythmia or hypertension (3) Aortic aneurysm (4) Combined with asthma or active hemoptysis (5) pneumothorax (6) High mental tension and unable to complete bronchoscopy (7) Severe superior vena cava obstruction syndrome (8) The body organ extreme failure 8. With respiratory infection or Acute Exacerbation of Chronic Obstructive Pulmonary Disease in past 1 month; 9. Involved in other clinical trial in past 1 month.

Design outcomes

Primary

MeasureTime frame
dyspnea scores;life quality score;6 Minutes Walk Distance, 6MWD;

Secondary

MeasureTime frame
cell factor;

Countries

China

Contacts

Public ContactWang Yiangyu

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

wxy769400@163.com+86 13653862360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026